Hepion pharmaceuticals, inc. (CTRV)
Income statement / TTM
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13
Costs and expenses:
Research and development

3,184

3,162

4,483

5,851

7,593

9,751

11,547

12,684

13,368

14,485

13,651

14,416

14,658

14,383

15,019

14,584

14,003

11,785

8,403

5,032

2,499

684

314

217

0

0

0

General and administrative

4,586

5,361

5,981

6,803

7,000

6,530

6,720

6,915

7,277

7,499

7,371

7,185

6,687

6,454

5,786

5,801

6,127

5,936

5,556

4,421

3,016

1,889

1,357

724

0

0

0

Total operating expenses

-

-

0

0

-

-

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from operations

-7,770

-8,523

-10,465

-12,654

-14,594

-16,281

-18,267

-19,599

-20,646

-21,985

-21,023

-21,601

-21,346

-20,838

-20,805

-20,386

-20,131

-17,721

-13,959

-9,454

-5,515

-2,574

-1,672

-942

0

0

0

Other income (expense):
Change in fair value of debt

-179

-190

-136

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

-

610

827

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative instruments-warrants and contingent consideration

558

1,074

4,712

4,517

5,056

5,454

1,753

8,964

5,618

4,228

4,224

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

12

13

0

0

0

Total other income (expense)

-

-

-

0

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-3,608

-8,859

0

0

0

Change in fair value of derivative instruments-warrants

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

387

9,234

0

0

-

0

-

-

-

Loss before income taxes

-7,946

-8,357

-6,695

-8,742

-9,985

-11,097

-16,714

-10,635

-15,027

-17,756

0

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

Income tax benefit

-

-

0

-

-536

0

0

0

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-6,718

-7,396

-5,734

-8,742

-9,449

-8,613

-14,230

-8,151

-13,079

-15,848

-14,891

0

0

0

-

0

0

0

-

-

-14,054

0

-

0

0

-

-

Deemed dividend (see note 6)

5,442

14,250

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

0

-

-

-

-

-

-

-

Series A and B convertible preferred stock beneficial conversion feature accreted as a dividend

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

Comprehensive Loss Attributable to Common Shareholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

Net loss attributable to common shareholders

-12,161

-12,487

-19,622

-17,218

-17,901

-17,419

-14,230

0

0

0

-

-

-

-

-

-

-

-

-

-

0

-

-5,280

-9,802

0

0

0

Weighted Average Common Shares Outstanding:
Basic

-

-

-

17,508

-

-

-

10,124

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

-

-

-

17,508

-

-

-

10,124

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted

-

3,453

859

-

-

202

152

-

-

7,506

7,506

63,301

60,053

37,919

-

27,297

26,642

22,289

22,260

22,273

22,273

20,211

18,536

14,735

9,000

9,000

9,000

Net loss per Common Share: (see note 12)
Basic

-

-

-

-0.11

-

-

-

-0.27

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

-

-

-

-0.11

-

-

-

-0.27

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted

-

-0.53

-7.48

-

-

-44.27

-26.45

-

-

-0.77

0.27

-0.12

-0.08

-0.13

-

-0.14

-0.11

-0.22

-0.26

-0.33

-0.36

-0.07

0.26

-0.63

-0.02

-0.02

-0.02